Researchers, therefore, recommend SARS-COV-2 vaccination in all patients diagnosed with IBD and receiving anti-TNF agents (Lin et al., 2022), although diminished humoral responses have been noted in those specific populations (Bordalo Ferreira et al., 2023). Here, TNF is linked to inflammatory bowel disease.